Coverage
-
November 04, 2016
Avalanche Biotechnologies Inc. on Thursday won dismissal in California federal court of an investor suit accusing it of misleading investors about the effectiveness of its gene therapy for vision loss before its initial public offering, but the judge said the investors can try again with an amended complaint.
3 other articles on this case.
View all »